{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:14:11Z","timestamp":1792588451638,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"publisher","award":["NIDA P30 DA035772"],"award-info":[{"award-number":["NIDA P30 DA035772"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Medications for opioid and alcohol use disorder (MOUD\/MAUD) are efficacious, important components of relapse prevention care, and markedly underused. Yet, not all programs treating substance use disorders (SUD) offer them. Using the Substance Abuse and Mental Health Services Administration's 2022 National Substance Use and Mental Health Services Survey (N-SUMHSS), for outpatient programs (excluding opioid treatment programs) that provided \u201cprimarily SUD services\u201d (SUD) or \u201cprimarily mental health but also SUD services\u201d (MH\/SUD; N = 9921 programs), we identified program characteristics associated with providing MOUD or MAUD, focusing on potential policy levers (state licensure\/certification, national organization accreditation) that could increase MOUD\/MAUD access. We found that only approximately half (51%) provide MOUD and fewer (45%) provide MAUD. State licensure\/certification was negatively associated with providing these medications, while national organization accreditation was positively associated. However, states varied widely in these associations. Additionally, SUD programs were less likely to offer MOUD\/MAUD compared with MH\/SUD programs. These findings demonstrate missed policy opportunities for states and national accreditation organizations to move SUD care into evidence-based practice.<\/jats:p>","DOI":"10.1093\/haschl\/qxaf040","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:01:01Z","timestamp":1744178461000},"source":"Crossref","is-referenced-by-count":4,"title":["Opioid and alcohol use disorder medication availability in outpatient care: national estimates &amp; potential policy levers"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1828-9098","authenticated-orcid":false,"given":"Alisa B","family":"Busch","sequence":"first","affiliation":[{"name":"McLean Hospital , Belmont, MA 02478, USA"},{"name":"Department of Psychiatry, Harvard Medical School , Boston, MA 02115, USA"},{"name":"Department of Health Care Policy, Harvard Medical School , Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon-Lise T","family":"Normand","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School , Boston, MA 02115, USA"},{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health , Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2659-7082","authenticated-orcid":false,"given":"Constance M","family":"Horgan","sequence":"additional","affiliation":[{"name":"Heller School for Social Policy and Management, Brandeis University, Waltham, MA 02453 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly F","family":"Greenfield","sequence":"additional","affiliation":[{"name":"McLean Hospital , Belmont, MA 02478, USA"},{"name":"Department of Psychiatry, Harvard Medical School , Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiden A","family":"Huskamp","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School , Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Reif","sequence":"additional","affiliation":[{"name":"Heller School for Social Policy and Management, Brandeis University, Waltham, MA 02453 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2025043003563898200_qxaf040-B1","article-title":"Substance Abuse and Mental Health Services Administration (SAMHSA). 2023 NSDUH Detailed Tables | CBHSQ Data"},{"key":"2025043003563898200_qxaf040-B2","author":"Alcohol-Related Emergencies and Deaths in the United States | National Institute on Alcohol Abuse and Alcoholism (NIAAA)"},{"issue":"5","key":"2025043003563898200_qxaf040-B3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamapsychiatry.2019.4170","article-title":"All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis","volume":"77","author":"Larney","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"2025043003563898200_qxaf040-B4","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:135849","volume-title":"Drug Overdose Deaths in the United States, 2002-2022","author":"Spencer","year":"2023"},{"issue":"7","key":"2025043003563898200_qxaf040-B5","doi-asserted-by":"publisher","first-page":"e2326346","DOI":"10.1001\/jamanetworkopen.2023.26346","article-title":"Trends in alcohol-related deaths by sex in the US, 1999-2020","volume":"6","author":"Karaye","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2025043003563898200_qxaf040-B6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.15585\/mmwr.mm7308a1","article-title":"Deaths from excessive alcohol use\u2014United States, 2016\u20132021","volume":"73","author":"Esser","year":"2024","journal-title":"MMWR"},{"key":"2025043003563898200_qxaf040-B7","volume-title":"VA\/DoD Clinical Practice Guideline for the Management of Substance Use Disorders","year":"2021"},{"issue":"2S","key":"2025043003563898200_qxaf040-B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","author":"","year":"2020","journal-title":"J Addict Med."},{"issue":"6","key":"2025043003563898200_qxaf040-B9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1176\/appi.ajp.20230273","article-title":"Fentanyl and other opioid use disorders: treatment and research needs","volume":"180","author":"Volkow","year":"2023","journal-title":"Am J Psychiatry"},{"issue":"17","key":"2025043003563898200_qxaf040-B10","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"2025043003563898200_qxaf040-B11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1001\/jama.2024.11913","article-title":"Treatment approaches for opioid use disorder offered in US substance use treatment facilities","volume":"332","author":"Park","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"2025043003563898200_qxaf040-B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Aff."},{"key":"2025043003563898200_qxaf040-B13","volume-title":"Tracking the Quality of Addiction Treatment Over Time and Across States: Using the Federal Government's \u201cSigns\u201d of Higher Quality","author":"Mark","year":"2020"},{"key":"2025043003563898200_qxaf040-B14","doi-asserted-by":"publisher","first-page":"108424","DOI":"10.1016\/j.jsat.2021.108424","article-title":"Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: a state-level trends analysis","volume":"132","author":"Solomon","year":"2022","journal-title":"J Subst Abuse Treat."},{"issue":"3","key":"2025043003563898200_qxaf040-B15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11414-007-9069-z","article-title":"Does state certification or licensure influence outpatient substance abuse treatment program practices?","volume":"34","author":"Chriqui","year":"2007","journal-title":"J Behav Health Serv Res"},{"key":"2025043003563898200_qxaf040-B16","volume-title":"Health Care Accreditation and Quality of Care: Exploring the Role of Accreditation and External Evaluation of Health Care Facilities and Organizations","year":"2022"},{"key":"2025043003563898200_qxaf040-B17","article-title":"Commission on Accreditation of Rehabilitation Facilities (CARF). CARF Standards Template Documents: Behavioral Health General Standards"},{"key":"2025043003563898200_qxaf040-B18","author":"Joint Commission Accreditation"},{"key":"2025043003563898200_qxaf040-B19","article-title":"Substance Abuse and Mental Health Services Administration (SAMHSA). National Substance Use and Mental Health Services Survey (N-SUMHSS), 2022: Codebook. Published online 2022"},{"key":"2025043003563898200_qxaf040-B20"},{"key":"2025043003563898200_qxaf040-B21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jhealeco.2018.06.004","article-title":"The role of health insurance on treatment for opioid use disorders: evidence from the affordable care act medicaid expansion","volume":"60","author":"Meinhofer","year":"2018","journal-title":"J Health Econ."},{"issue":"4","key":"2025043003563898200_qxaf040-B22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/MLR.0000000000000703","article-title":"Impact of medicaid expansion on medicaid-covered utilization of buprenorphine for opioid use disorder treatment","volume":"55","author":"Wen","year":"2017","journal-title":"Med Care."},{"issue":"5","key":"2025043003563898200_qxaf040-B23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.2105\/AJPH.2018.304338","article-title":"Impact of medicaid expansion on access to opioid analgesic medications and medication-assisted treatment","volume":"108","author":"Sharp","year":"2018","journal-title":"Am J Public Health"},{"issue":"2","key":"2025043003563898200_qxaf040-B24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US medicaid enrollees in 11 States, 2014-2018","volume":"326","author":"Donohue","year":"2021","journal-title":"JAMA"},{"key":"2025043003563898200_qxaf040-B25","volume-title":"Status of State Action on the Medicaid Expansion Decision"},{"issue":"4","key":"2025043003563898200_qxaf040-B26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jadohealth.2020.03.005","article-title":"Adolescent-serving addiction treatment facilities in the United States and the availability of medications for opioid use disorder","volume":"67","author":"Alinsky","year":"2020","journal-title":"J Adolesc Health"},{"key":"2025043003563898200_qxaf040-B27","doi-asserted-by":"publisher","first-page":"108060","DOI":"10.1016\/j.jsat.2020.108060","article-title":"Adoption of telemedicine services by substance abuse treatment facilities in the U.S","volume":"117","author":"Uscher-Pines","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"2025043003563898200_qxaf040-B28","doi-asserted-by":"publisher","first-page":"e1920843","DOI":"10.1001\/jamanetworkopen.2019.20843","article-title":"Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States","volume":"3","author":"Huhn","year":"2020","journal-title":"JAMA Netw Open."},{"key":"2025043003563898200_qxaf040-B29","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamapsychiatry.2024.0825","article-title":"Geographic penetration of private equity ownership in outpatient and residential behavioral health","volume":"81","author":"Zhu","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2025043003563898200_qxaf040-B30","doi-asserted-by":"publisher","first-page":"qxae076","DOI":"10.1093\/haschl\/qxae076","article-title":"Access to treatment before and after medicare coverage of opioid treatment programs","volume":"2","author":"Liu","year":"2024","journal-title":"Health Aff Sch."},{"issue":"6","key":"2025043003563898200_qxaf040-B31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jama.2023.26522","article-title":"Availability of long-acting injectable buprenorphine at substance use treatment facilities in 2021","volume":"331","author":"Vidyasagar","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"2025043003563898200_qxaf040-B32","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1377\/hlthaff.2023.01306","article-title":"Licensure policies may help states ensure access to opioid use disorder medication in specialty addiction treatment","volume":"43","author":"Kennedy-Hendricks","year":"2024","journal-title":"Health Aff."},{"key":"2025043003563898200_qxaf040-B33","volume-title":"State Regulations on Substance Use Disorder Programs and Counselors: An Overview","year":"2013"},{"key":"2025043003563898200_qxaf040-B34","doi-asserted-by":"publisher","first-page":"10.31478\/202004b","DOI":"10.31478\/202004b","article-title":"Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system","volume":"2020","author":"Madras","year":"2020","journal-title":"NAM Perspect."},{"issue":"4","key":"2025043003563898200_qxaf040-B35","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1097\/ADM.0000000000000918","article-title":"First-line medications for the outpatient treatment of alcohol use disorder: a systematic review of perceived barriers","volume":"16","author":"Gregory","year":"2022","journal-title":"J Addict Med"},{"key":"2025043003563898200_qxaf040-B36","doi-asserted-by":"publisher","first-page":"108900","DOI":"10.1016\/j.jsat.2022.108900","article-title":"Not in my treatment center: Leadership's perception of barriers to MOUD adoption","volume":"144","author":"Stewart","year":"2023","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"2025043003563898200_qxaf040-B37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1530-0277.2006.00022.x","article-title":"Advances in the pharmacotherapy of alcoholism: challenging misconceptions","volume":"30","author":"Kranzler","year":"2006","journal-title":"Alcohol Clin Exp Res."},{"issue":"1","key":"2025043003563898200_qxaf040-B38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.15288\/jsa.2000.61.134","article-title":"Alcoholics anonymous and the use of medications to prevent relapse: an anonymous survey of member attitudes","volume":"61","author":"Rychtarik","year":"2000","journal-title":"J Stud Alcohol"},{"key":"2025043003563898200_qxaf040-B39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jsat.2019.06.008","article-title":"State targeted response to the opioid crisis grants (opioid STR) program: preliminary findings from two case studies and the national cross-site evaluation","volume":"108","author":"High","year":"2020","journal-title":"J Subst Abuse Treat."},{"key":"2025043003563898200_qxaf040-B40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jsat.2019.06.015","article-title":"Implementation and evaluation of Missouri's medication first treatment approach for opioid use disorder in publicly-funded substance use treatment programs","volume":"108","author":"Winograd","year":"2020","journal-title":"J Subst Abuse Treat."},{"key":"2025043003563898200_qxaf040-B41","volume-title":"R3 Report: Enhanced Substance Use Disorder Standards for Behavioral Health Organizations","year":"2019"},{"key":"2025043003563898200_qxaf040-B42","volume-title":"Enhanced Substance Use Disorders Standards for Behavioral Health Organizations","year":"2019"},{"issue":"1","key":"2025043003563898200_qxaf040-B43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1176\/appi.ps.201100034","article-title":"Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders","volume":"63","author":"Knudsen","year":"2012","journal-title":"Psychiatr Serv"},{"issue":"1","key":"2025043003563898200_qxaf040-B44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1747-597X-3-17","article-title":"State policy influence on the early diffusion of buprenorphine in community treatment programs","volume":"3","author":"Ducharme","year":"2008","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025043003563898200_qxaf040-B45","article-title":"Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act.","year":"2018"},{"key":"2025043003563898200_qxaf040-B46","article-title":"Mandatory Medicaid State Plan Coverage of Medication-Assisted Treatment","author":"Centers for Medicare & Medicaid"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/4\/qxaf040\/62893383\/qxaf040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/4\/qxaf040\/62893383\/qxaf040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:56:47Z","timestamp":1745999807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxaf040\/8108910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxaf040","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,4,1]]},"article-number":"qxaf040"}}